Fluxergy
Medical diagnostics company Fluxergy has announced that it is 'the first company' to utilise in-kind Diagnostics Development Services from the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) to advance molecular testing and sample preparation capabilities on the Fluxergy platform.
Under NIAID's suite of preclinical services, NIAID-funded contractors will evaluate rapid nucleic acid extraction and purification methods compatible with the Fluxergy Test Card, with the goal of achieving high sensitivity, sample-to-answer molecular tests to be developed for gram-negative and fungal pathogens that cause sexually transmitted infections and bacterial and fungal vaginosis.
These integrated extraction capabilities will be required for the development of Fluxergy's sexually transmitted infection (STI) test and comprehensive vaginosis test.
"Fluxergy has had several successful collaborations with the United States Government, including our recent award from JPEO through the Henry Jackson Foundation for the development of a multimodal host-based early sepsis detection test," said Tej Patel, Fluxergy CEO. "This agreement with NIAID will allow us to accelerate progress toward commercialisation of a full menu of easy-to-use, cost-effective, and lab-quality tests of the Fluxergy Platform to address significant accessibility and affordability issues with point-of-care diagnostics available today."
Many healthcare providers use syndromic management to diagnose and prescribe treatment to patients, leading to inadequate treatment or eventual antimicrobial resistance. By simplifying the workflow and lowering the cost of testing, point-of-care diagnostics can provide a solution to these current issues in STI management.
This announcement follows the news of a previous partnership launched earlier this year for Fluxergy. In January, the company announced they had formally partnered with Austere environments Consortium for Enhanced Sepsis Outcomes (ACESO) through a grant administered by The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) to evaluate the feasibility of bringing rapid sepsis results to resource-limited settings.
